These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 2300383)

  • 1. High-dose 4'-epiadriamycin for treatment of breast cancer refractory to standard dose anthracycline chemotherapy: achievement of second responses.
    Bezwoda WR; Dansey R; Seymour L
    Oncology; 1990; 47(1):4-8. PubMed ID: 2300383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epirubicin high-dose therapy in advanced breast cancer: preliminary clinical data. Epirubicin as a single agent in breast cancer.
    Neri B; Pacini P; Bartalucci S; Moroni F; Menchi I; Cappellini M
    Int J Clin Pharmacol Ther Toxicol; 1989 Aug; 27(8):388-91. PubMed ID: 2793274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
    Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer.
    Perez DJ; Harvey VJ; Robinson BA; Atkinson CH; Dady PJ; Kirk AR; Evans BD; Chapman PJ
    J Clin Oncol; 1991 Dec; 9(12):2148-52. PubMed ID: 1960557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I-II trial of high-dose epirubicin in patients with lymphoma.
    Case DC; Gams R; Ervin TJ; Boyd MA; Oldham FB
    Cancer Res; 1987 Dec; 47(23):6393-6. PubMed ID: 3479245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epirubicin-containing high-dose chemotherapy followed by autologous hematopoietic progenitor cell transfusion for patients with chemotherapy-sensitive metastatic breast cancer: results of 5-year follow-up.
    Ito Y; Mukaiyama T; Ogawa M; Mizunuma N; Takahashi S; Aiba K; Horikoshi N
    Cancer Chemother Pharmacol; 1999; 43(1):8-12. PubMed ID: 9923535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epirubicin: is it like doxorubicin in breast cancer? A clinical review.
    Khasraw M; Bell R; Dang C
    Breast; 2012 Apr; 21(2):142-9. PubMed ID: 22260846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Protective effect of dexrazoxane on cardiotoxicity in breast cancer patients who received anthracycline-containing chemotherapy].
    Wang P; Zhang S; Zhang XB; Li WJ; Hao XM; Zhang J
    Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):135-9. PubMed ID: 23714670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
    Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
    De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
    Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.
    Ottosson S; Magnusson K; Hultborn R
    Anticancer Res; 1999; 19(5C):4429-34. PubMed ID: 10650787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: results of a clinical phase II study.
    Köhler U; Olbricht SS; Fuechsel G; Kettner E; Richter B; Ridwelski K
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-40-S17-43. PubMed ID: 9374091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epirubicin plus docetaxel in metastatic breast cancer: escalating dose does not improve efficacy. A phase II study.
    Fabi A; Papaldo P; Pino MS; Ferretti G; Carlini P; Pacetti U; Di Cosimo S; Nardoni C; Giannarelli D; Sacchi I; Cognetti F
    Anticancer Res; 2004; 24(3b):1963-7. PubMed ID: 15274385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer.
    Lück HJ; Du Bois A; Thomssen C; Lisboa B; Untch M; Köhler G; Hecker D
    Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):34-7. PubMed ID: 9144689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A phase I trial of 4'-epiadriamycin].
    Ogawa M; Ikeda K; Inagaki J; Horikoshi N; Inoue K; Nakada K; Usui N; Okada Y; Adachi K; Tada A
    Gan To Kagaku Ryoho; 1984 Apr; 11(4):926-9. PubMed ID: 6586111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).
    Ejlertsen B; Mouridsen HT; Langkjer ST; Andersen J; Sjöström J; Kjaer M;
    J Clin Oncol; 2004 Jun; 22(12):2313-20. PubMed ID: 15197192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer.
    Schwartsmann G; Mans DR; Menke CH; Xavier N; Caleffi M; Ferreira Filho AF; Schunemann H; Kalakun L; Koya R; Pohlman P; Venegas LF
    Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):24-9. PubMed ID: 9144687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer.
    Espinosa E; Morales S; Borrega P; Casas A; Madroñal C; Machengs I; Illarramendi JA; Lizón J; Moreno JA; Belón J; Janáriz J; de la Puente M; Checa T; Mel JR; González Barón M
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):546-52. PubMed ID: 15316749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of doxorubicin versus epirubicin in advanced breast cancer.
    Brambilla C; Rossi A; Bonfante V; Ferrari L; Villani F; Crippa F; Bonadonna G
    Cancer Treat Rep; 1986 Feb; 70(2):261-6. PubMed ID: 3456271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.